Inscripción
profesionales sanitarios
para pacientes y familiares
A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erlotinib in recurrent/metastatic head and neck squamous-cell carcinomas - ESMO Open
A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erloti...
We conducted a randomized phase II trial to evaluate whether adding erlotinib to platinum/docetaxel improves clinical ...
www.esmoopen.com
No good news for the @BioNTech_Group mRNA HPV vaccine in 1st L R/M #HNSCC in the latest interim analysis
🔴 Negative PFS
⏱️Awaiting results for Overall Survival in next analyses (coprimary endpoint)
@OncoAlert @brunolarvol @OncBrothers
Neoadjuvant PIK3CA Inhibition With Alpelisib in Head and Neck Squamous Cell Cancer: A Window-of-Opportunity Trial and Biomarker Study | JCO Oncology Advances
Neoadjuvant PIK3CA Inhibition With Alpelisib in Head and Neck Squamous Cell Cancer: A Window-of-O...
PurposePIK3CA-activating mutations and amplifications are common in both human papillomavirus (HPV)–positive and HPV-negativ...
ascopubs.org
A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erlotinib in recurrent/metastatic head and neck squamous-cell carcinomas - ESMO Open
A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erloti...
We conducted a randomized phase II trial to evaluate whether adding erlotinib to platinum/docetaxel improves clinical ...
www.esmoopen.com
No good news for the @BioNTech_Group mRNA HPV vaccine in 1st L R/M #HNSCC in the latest interim analysis
🔴 Negative PFS
⏱️Awaiting results for Overall Survival in next analyses (coprimary endpoint)
@OncoAlert @brunolarvol @OncBrothers
Neoadjuvant PIK3CA Inhibition With Alpelisib in Head and Neck Squamous Cell Cancer: A Window-of-Opportunity Trial and Biomarker Study | JCO Oncology Advances
Neoadjuvant PIK3CA Inhibition With Alpelisib in Head and Neck Squamous Cell Cancer: A Window-of-O...
PurposePIK3CA-activating mutations and amplifications are common in both human papillomavirus (HPV)–positive and HPV-negativ...
ascopubs.org
A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erlotinib in recurrent/metastatic head and neck squamous-cell carcinomas - ESMO Open
A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erloti...
We conducted a randomized phase II trial to evaluate whether adding erlotinib to platinum/docetaxel improves clinical ...
www.esmoopen.com
No good news for the @BioNTech_Group mRNA HPV vaccine in 1st L R/M #HNSCC in the latest interim analysis
🔴 Negative PFS
⏱️Awaiting results for Overall Survival in next analyses (coprimary endpoint)
@OncoAlert @brunolarvol @OncBrothers
Neoadjuvant PIK3CA Inhibition With Alpelisib in Head and Neck Squamous Cell Cancer: A Window-of-Opportunity Trial and Biomarker Study | JCO Oncology Advances
Neoadjuvant PIK3CA Inhibition With Alpelisib in Head and Neck Squamous Cell Cancer: A Window-of-O...
PurposePIK3CA-activating mutations and amplifications are common in both human papillomavirus (HPV)–positive and HPV-negativ...
ascopubs.org
TTCC en cifras
